NewcelX (NCEL) Treasury Shares (2021 - 2023)

NewcelX (NCEL) posted quarterly Treasury Shares of $64858.0 for Q4 2023, up 200.0% quarter-over-quarter from -$64858.0 in Q2 2023.

NewcelX (NCEL) Treasury Shares (2021 - 2023) Analysis & Trends

NewcelX (NCEL) has reported Treasury Shares for 3 consecutive years, with $64858.0 the latest figure, recorded in Q4 2023.

In Q4 2023, Treasury Shares changed N/A year-over-year to $64858.0; the TTM figure through Dec 2023 stood at $64858.0 (changed N/A YoY), while the FY2023 annual figure was $64858.0, changed N/A from the prior year.
Treasury Shares advanced to $64858.0 in Q4 2023 per NCEL's latest filing, from -$64858.0 in the prior quarter.
Across five years, Treasury Shares topped out at $3.2 million in Q2 2023 and bottomed at $1.5 million in Q4 2021.
Historically, Treasury Shares has averaged $2.4 million across 3 years, with a median of $2.5 million in 2022.
On a YoY basis, Treasury Shares climbed as much as 82.33% in 2023 and fell as far as 82.33% in 2023.
NewcelX's Treasury Shares stood at $29497.0 in 2021, then sank by 220.6% to -$35572.0 in 2022, then soared by 282.33% to $64858.0 in 2023.
Business Quant data shows NCEL's Treasury Shares at $64858.0 in Q4 2023, -$64858.0 in Q2 2023, and -$35572.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	2.72 Mn
10	NewcelX	12.54 Mn	10.34 Mn	-	-

Download Data